Hypothalamic-Pituitary Axis (HPA)

📋 Key Information Summary

📋

The hypothalamic–pituitary axis (HPA) governs growth, reproduction, metabolism, stress response, water balance and circadian rhythm via a hierarchical three-tier endocrine system.
The hypothalamus secretes releasing/inhibiting hormones (CRH, GnRH, TRH, GHRH, somatostatin, dopamine) that regulate anterior pituitary trophic hormones.
Six anterior pituitary hormones — ACTH, TSH, LH, FSH, GH, PRL — each act on peripheral target glands with negative feedback maintaining homeostasis.
Posterior pituitary releases ADH (vasopressin) and oxytocin, synthesised in the hypothalamus and stored in the posterior lobe.
Negative feedback from cortisol, thyroid hormones, oestradiol/testosterone, and IGF-1 at both hypothalamic and pituitary levels is the primary regulatory mechanism.
Dynamic stimulation testing (insulin tolerance test, glucagon stimulation test, ACTH stimulation test) is the gold standard for assessing HPA reserve in suspected hypopituitarism.
The insulin tolerance test (ITT) remains the gold standard for GH and cortisol reserve assessment in Australia but requires cardiac monitoring and experienced endocrine supervision.
TRH and GnRH stimulation tests assess TSH and gonadotrophin reserve respectively; the short Synacthen test is the most practical screening test for adrenal reserve.
Pituitary adenomas (both functioning and non-functioning) account for the majority of HPA pathology encountered in Australian endocrine practice.
Hypopituitarism may present insidiously; panhypopituitarism is life-threatening if adrenal insufficiency is not recognised and treated before other hormone replacement.
Cushing disease (ACTH-secreting pituitary adenoma) and acromegaly (GH-secreting adenoma) require specialist management at tertiary centres with multidisciplinary pituitary teams.
Aboriginal and Torres Strait Islander peoples have higher rates of diabetes and metabolic syndrome, which may complicate HPA-related endocrine assessment; culturally safe care and awareness of remote access barriers are essential.

🎧 Audio Brief

The corporate hierarchy of your hormones

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

The hypothalamic–pituitary axis (HPA) is the master regulatory system of endocrine function. It operates through a three-tiered hierarchical model: the hypothalamus produces releasing and inhibiting hormones, the anterior pituitary secretes trophic hormones, and peripheral target glands produce end-effectors that feed back to modulate upstream secretion. This elegant feedback architecture governs growth, reproduction, thyroid function, adrenal stress responses, water balance, lactation and circadian rhythm.

In Australian clinical practice, disorders of the HPA encompass pituitary adenomas (both functioning and non-functioning), hypopituitarism from any cause (surgery, radiation, infiltrative disease, traumatic brain injury, Sheehan syndrome), central diabetes insipidus, and syndromes of inappropriate hormone excess such as Cushing disease, acromegaly and prolactinoma.

Pituitary adenomas are found incidentally in approximately 10–15% of the general population on high-resolution MRI, though clinically significant tumours are far less common. Non-functioning pituitary adenomas are the most frequently encountered subtype in Australian endocrine clinics. Prolactinomas are the most common functioning adenoma, with an estimated prevalence of 50–60 per 100,000 in women and 10–15 per 100,000 in men. Acromegaly has an estimated prevalence of 40–60 per million in Australia, with a diagnostic delay of 7–10 years being common. Cushing disease incidence is approximately 1–2 per million per year.

Traumatic brain injury (TBI) is an increasingly recognised cause of hypopituitarism, with studies from Australian trauma centres reporting anterior pituitary deficiency in 25–50% of moderate-to-severe TBI survivors. Awareness of this association is critical for long-term follow-up.

Anatomy & Hormones of the HPA

Hypothalamic Releasing & Inhibiting Hormones

The hypothalamus lies in the diencephalon, inferior to the third ventricle and superior to the pituitary stalk (infundibulum). Neurosecretory neurons synthesise releasing and inhibiting peptides that travel via the hypophyseal portal system to the anterior pituitary.

Hypothalamic Hormone	Abbreviation	Action on Anterior Pituitary
Corticotrophin-releasing hormone	CRH	Stimulates ACTH release from corticotrophs
Thyrotrophin-releasing hormone	TRH	Stimulates TSH (and PRL) release from thyrotrophs/lactotrophs
Gonadotrophin-releasing hormone	GnRH	Stimulates LH and FSH release from gonadotrophs (pulsatile secretion required)
Growth hormone–releasing hormone	GHRH	Stimulates GH release from somatotrophs
Somatostatin (SRIF)	SS	Inhibits GH and TSH release
Dopamine	DA	Inhibits PRL release from lactotrophs (tonic inhibition)

Anterior Pituitary Hormones

The anterior pituitary (adenohypophysis) contains five major cell types, each producing a characteristic hormone. The somatotrophs (producing GH) constitute approximately 50% of anterior pituitary cells, making GH excess (acromegaly) and GH deficiency the most common anterior pituitary disorders.

Cell Type	Hormone	Target Gland / Tissue	End-Product / Effect
Corticotroph	ACTH	Adrenal cortex	Cortisol (and adrenal androgens)
Thyrotroph	TSH	Thyroid gland	T3, T4
Gonadotroph	LH, FSH	Gonads	Oestradiol / progesterone, testosterone, gametogenesis
Somatotroph	GH	Liver, bone, soft tissues	IGF-1, linear growth, metabolic effects
Lactotroph	PRL	Mammary gland	Lactation, gonadal suppression

Posterior Pituitary Hormones

The posterior pituitary (neurohypophysis) stores and releases two hormones synthesised in the supraoptic and paraventricular nuclei of the hypothalamus:

ADH (arginine vasopressin, AVP): Regulates water reabsorption via V2 receptors in the renal collecting duct. Deficiency causes central diabetes insipidus; excess causes SIADH.
Oxytocin: Stimulates uterine contraction during labour and milk ejection during lactation. Emerging evidence supports a role in social bonding and behaviour.

Regulation & Feedback Mechanisms

The Negative Feedback Model

The HPA is regulated by classical negative feedback loops. Each target gland hormone inhibits the secretion of its upstream trophic hormone at both the hypothalamic and pituitary levels. This maintains circulating hormone concentrations within a narrow physiological range.

Hypothalamic–Pituitary–Adrenal (HPA) axis: Cortisol suppresses CRH and ACTH secretion. The diurnal cortisol rhythm (peak at ~08:00, nadir at midnight) is driven by the suprachiasmatic nucleus and sleep–wake cycle.
Hypothalamic–Pituitary–Thyroid (HPT) axis: T3 (both circulating and locally converted from T4 via type 2 deiodinase in the pituitary) suppresses TRH and TSH.
Hypothalamic–Pituitary–Gonadal (HPG) axis: Oestradiol and testosterone suppress GnRH, LH and FSH. Inhibin B (from Sertoli cells / granulosa cells) selectively suppresses FSH.
GH–IGF-1 axis: IGF-1 (produced by the liver in response to GH) feeds back to suppress GH secretion at the pituitary and hypothalamus. Ghrelin (stomach) and somatostatin (hypothalamus) provide additional regulation.

Pulsatile Secretion

Several HPA hormones are secreted in a pulsatile fashion rather than continuously. GnRH must be delivered in pulses (every 60–90 minutes) to stimulate LH and FSH; continuous GnRH paradoxically down-regulates gonadotrophs (the basis for GnRH agonist therapy). GH is secreted in bursts, predominantly during slow-wave sleep. These pulsatile patterns are clinically important when interpreting single hormone measurements.

The Hypophyseal Portal System

The hypophyseal portal system is a specialised capillary network connecting the median eminence of the hypothalamus to the anterior pituitary. It delivers releasing and inhibiting hormones in high local concentration, bypassing the systemic circulation. Disruption of the portal system (e.g., by pituitary stalk transection in trauma or surgery) causes hypopituitarism and paradoxical hyperprolactinaemia (loss of tonic dopamine inhibition).

⚠️

Clinical pearl: A patient with panhypopituitarism and elevated prolactin likely has stalk effect (interruption of dopaminergic inhibition). If the prolactin is markedly elevated (>2,000 mU/L), a prolactinoma should be suspected instead. Distinguishing stalk effect from macroprolactinoma is critical for management.

Dynamic Testing

Dynamic stimulation tests are essential for evaluating the functional reserve of the HPA. Basal hormone levels may be misleadingly normal, particularly for GH and ACTH, which have pulsatile or diurnal secretion patterns. All dynamic tests should be performed in specialist endocrine units with appropriate monitoring and resuscitation facilities.

Insulin Tolerance Test (ITT)

🚨

Contraindicated in: Ischaemic heart disease, epilepsy, elderly (>65 years), severe hypopituitarism (basal cortisol <100 nmol/L). Must be performed under continuous medical supervision with IV access and 50% glucose available.

The ITT remains the gold standard test for both GH and cortisol reserve assessment in Australia. Regular insulin (Actrapid®) 0.1–0.15 units/kg IV is administered to achieve symptomatic hypoglycaemia (blood glucose <2.2 mmol/L). Adequate hypoglycaemia must be confirmed; the test is invalid otherwise.

Parameter	Normal Response	Interpretation
Peak cortisol	≥500 nmol/L	Adequate adrenal reserve; <500 nmol/L suggests adrenal insufficiency
Peak GH	≥5 µg/L (varies by assay)	Adequate GH reserve; lower thresholds suggest GHD

Short Synacthen Test (SST)

The SST is the most widely used screening test for adrenal reserve in Australian hospitals. Synacthen (tetracosactide 250 µg IM or IV) is administered and serum cortisol measured at 0, 30 and 60 minutes. A peak cortisol ≥500 nmol/L at 30 or 60 minutes indicates adequate adrenal reserve. It is safe, widely available on MBS, and does not require endocrine supervision — making it the preferred first-line test in the general ward or ED setting.

💉

Tetracosactide (Synacthen)

Synacthen® · ACTH analogue

Dose (SST) 250 µg IM or IV

Sampling Cortisol at 0, 30, 60 minutes

Normal response Peak cortisol ≥500 nmol/L

PBS status ✔ PBS General Benefit

Glucagon Stimulation Test (GST)

The GST is an alternative to the ITT for patients in whom insulin-induced hypoglycaemia is contraindicated. Glucagon 1 mg IM is administered and cortisol and GH measured at 0, 90, 120, 150 and 180 minutes. Normal response: peak cortisol ≥500 nmol/L and peak GH ≥3 µg/L. Nausea is a common side effect. The GST is available at major Australian endocrine centres.

TRH Stimulation Test

TRH (protirelin) 200 µg IV is administered with TSH measured at 0, 20 and 60 minutes. A normal TSH rise (increment ≥2 mU/L from baseline) excludes secondary hypothyroidism. In Australia, protirelin has limited commercial availability and the test is largely superseded by a combination of basal TSH and free T4 measurement, with clinical context.

GnRH Stimulation Test

GnRH 100 µg IV is administered with LH and FSH measured at 0, 30 and 60 minutes. An adequate LH rise (increment ≥2 IU/L) suggests intact gonadotroph reserve. The test is helpful in differentiating hypothalamic from pituitary causes of hypogonadism, particularly in the workup of delayed puberty.

GH Stimulation Tests

Because GH secretion is pulsatile, a random GH level is unreliable. Two stimulation tests are required to confirm adult GH deficiency (GHD). In Australia, the ITT is preferred; the GST or macimorelin test are alternatives. IGF-1 alone cannot exclude GHD, as up to 30% of adults with confirmed GHD have a normal IGF-1 level.

ℹ️

MBS note: The insulin tolerance test (MBS item 12204) and the Synacthen test (MBS item 12200) are Medicare-rebatable when performed in a recognised endocrine investigation unit. The glucagon stimulation test may be billed under an itemised protocol at specialist discretion.

Clinical Disorders of the HPA

Hypopituitarism

Hypopituitarism refers to deficiency of one or more anterior pituitary hormones. Causes include pituitary adenomas (non-functioning and functioning), craniopharyngioma, pituitary surgery or radiotherapy, traumatic brain injury, subarachnoid haemorrhage, Sheehan syndrome, lymphocytic hypophysitis, haemochromatosis, sarcoidosis and infiltrative disorders.

🚨

Critical safety point: In panhypopituitarism, cortisol replacement MUST be initiated BEFORE levothyroxine. Starting thyroxine in an adrenal-deficient patient increases cortisol metabolism and can precipitate an adrenal crisis. Always check and treat the adrenal axis first.

Replacement therapy — order of priority:

💊

Hydrocortisone

Hydrocortone® · Generic · Cortisol replacement

Adult dose 10–15 mg PO morning, 5–10 mg PO afternoon (split dose)

Paediatric dose 8–12 mg/m²/day PO in 2–3 divided doses

Stress dosing Double or triple dose for febrile illness; IV hydrocortisone 50–100 mg for vomiting, surgery, major trauma

PBS status ✔ PBS General Benefit

💊

Levothyroxine

Oroxine® · Eutroxsig® · T4 replacement

Adult dose 50–150 µg PO daily (titrate to mid-normal free T4)

Key note In central hypothyroidism, monitor free T4 (NOT TSH) — TSH may be low or inappropriately normal

PBS status ✔ PBS General Benefit

💊

Testosterone

Reandron 1000® · Androderm® · Hypogonadal replacement

Adult dose (IM) 1000 mg IM every 10–14 weeks (Reandron 1000)

Adult dose (transdermal) Androderm 2 mg/day or 4 mg/day patch

Target Mid-normal total testosterone (12–20 nmol/L)

PBS status ⚠ PBS Authority Required

Prolactinoma

Prolactinomas are the most common functioning pituitary adenoma. Microprolactinomas (<10 mm) predominate in women of reproductive age; macroprolactinomas (>10 mm) are more common in men. Elevated prolactin causes amenorrhoea, galactorrhoea, infertility in women, and erectile dysfunction, reduced libido and hypogonadism in men.

💊

Cabergoline

Cabaser® / Dostinex® · Dopamine agonist

Adult dose 0.25–0.5 mg PO twice weekly; titrate to 1–2 mg/week as needed

Key note First-line agent; superior efficacy and tolerability vs bromocriptine. Monitor for cardiac valve regurgitation at doses >2 mg/week

PBS status ✔ PBS General Benefit

💊

Bromocriptine

Parlodel® · Dopamine agonist

Adult dose 1.25–2.5 mg PO daily with food; titrate to 5–15 mg/day in divided doses

Key note Second-line; more side effects (nausea, postural hypotension). Preferred in pregnancy if dopamine agonist required

PBS status ✔ PBS General Benefit

Cushing Disease

Cushing disease refers specifically to ACTH-secreting pituitary adenoma causing hypercortisolism. It accounts for approximately 70% of endogenous Cushing syndrome cases. Clinical features include central obesity, moon face, supraclavicular fat pads, purple striae, proximal myopathy, easy bruising, glucose intolerance, hypertension, osteoporosis and psychiatric disturbance.

⚠️

Diagnosis requires: Two positive screening tests (24-hour urinary free cortisol, late-night salivary cortisol, or 1 mg overnight dexamethasone suppression test) followed by plasma ACTH measurement and pituitary MRI. Inferior petrosal sinus sampling (IPSS) may be needed to confirm pituitary vs ectopic ACTH source.

First-line treatment: Transsphenoidal pituitary surgery by an experienced neurosurgeon (remission rate 65–90% for microadenomas). Second-line options include pituitary radiotherapy, bilateral adrenalectomy, and steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat — specialist use).

Acromegaly

Acromegaly is caused by a GH-secreting pituitary adenoma in >95% of cases. Chronic GH/IGF-1 excess leads to acral enlargement, coarsened facial features, prognathism, soft tissue swelling, arthralgia, carpal tunnel syndrome, obstructive sleep apnoea, cardiomyopathy, colonic polyps and diabetes mellitus.

Treatment: Transsphenoidal surgery is first-line. Adjunctive therapy includes somatostatin receptor ligands (octreotide LAR, lanreotide), GH receptor antagonist (pegvisomant), and cabergoline for mild IGF-1 elevation. Pegvisomant is PBS-listed under authority for acromegaly refractory to somatostatin analogues.

💊

Octreotide LAR

Sandostatin LAR® · Somatostatin analogue

Adult dose 20–30 mg IM every 4 weeks

PBS status ⚠ PBS Authority Required

💊

Pegvisomant

Somavert® · GH receptor antagonist

Adult dose 10 mg SC daily; titrate to 30 mg/day (max) based on IGF-1

Key note Monitor LFTs; discontinue if transaminases >3× ULN. Can cause tumour growth in ~3%

PBS status 🔒 PBS Authority Required — Specialist

Central Diabetes Insipidus (CDI)

CDI results from deficient ADH secretion, causing polyuria (>3 L/day), polydipsia, and the passage of dilute urine (urine osmolality <300 mOsm/kg). Aetiology includes pituitary surgery, trauma, craniopharyngioma, Langerhans cell histiocytosis, and autoimmune hypophysitis. Idiopathic CDI accounts for 25–50% of cases.

💊

Desmopressin (DDAVP)

Minirin® · Synthetic ADH analogue

Adult dose (intranasal) 10–20 µg intranasally once or twice daily

Adult dose (oral) 100–200 µg PO two to three times daily

Paediatric dose 5–10 µg intranasally daily or 50–100 µg PO daily

Cautions Hyponatraemia risk — instruct patients to allow some thirst before redosing. Hold during intercurrent illness with reduced fluid intake

PBS status ✔ PBS General Benefit

Syndrome of Inappropriate ADH Secretion (SIADH)

SIADH is characterised by euvolaemic hyponatraemia with inappropriately concentrated urine. Common causes in Australian practice include CNS disorders (meningitis, encephalitis, stroke), pulmonary disease (pneumonia, small-cell lung carcinoma), medications (SSRIs, carbamazepine, cyclophosphamide) and post-operative state. Management centres on treating the underlying cause, fluid restriction (500–1000 mL/day), and in severe/refractory cases, salt tablets with loop diuretics or tolvaptan.

Investigations

A systematic approach to HPA investigation includes basal hormone measurement, dynamic stimulation testing, and anatomical imaging. The following table summarises key investigations and their availability in Australia.

Available

Serum cortisol (08:00–09:00)

Basal screen. <100 nmol/L suggests insufficiency; >400 nmol/L makes it unlikely. MBS-rebatable.

Available

ACTH (08:00–09:00 plasma)

Differentiates primary (high ACTH) from secondary/tertiary (low/normal ACTH) adrenal insufficiency.

Available

Short Synacthen test

First-line adrenal reserve test. 250 µg Synacthen IM/IV; cortisol at 0, 30, 60 min. Peak ≥500 nmol/L normal.

Specialist

Insulin tolerance test

Gold standard GH + cortisol reserve. Requires cardiac monitoring, endocrine supervision. MBS item 12204.

Specialist

Glucagon stimulation test

ITT alternative. 1 mg IM glucagon; cortisol + GH at 0, 90, 120, 150, 180 min.

Available

IGF-1

Screening for acromegaly and GH deficiency. Age- and sex-adjusted reference ranges required.

Available

Prolactin

Elevated in prolactinoma, stalk effect, medications. Levels >5,000 mU/L strongly suggest macroprolactinoma.

Available

Free T4 + TSH

Central hypothyroidism: low free T4 with inappropriately normal/low TSH. Monitor free T4, not TSH.

Available

LH, FSH, testosterone (men) / oestradiol (women)

Hypogonadotropic hypogonadism: low sex steroids with low/normal gonadotrophins.

Essential

MRI pituitary (gadolinium-enhanced)

Anatomical imaging of choice. 1.5T or 3T MRI with dynamic post-contrast sequences. Medicare-rebatable with endocrine indication.

Specialist

Inferior petrosal sinus sampling (IPSS)

Differentiates pituitary from ectopic ACTH in Cushing syndrome. Available at tertiary centres.

Available

24-hour urinary free cortisol

Screening for Cushing syndrome. Two collections recommended. MBS-rebatable.

Available

Late-night salivary cortisol

Non-invasive Cushing screen. Two samples recommended. Available through major pathology providers in Australia.

Special Populations

🤰 Pregnancy

Prolactinoma: Bromocriptine is preferred dopamine agonist in pregnancy. Cabergoline may be continued if conception occurs on it, but limited safety data. Discontinue after confirmation of pregnancy if safe to do so.

Adrenal insufficiency: Hydrocortisone is preferred (crosses placenta minimally). Increase dose by 50% in the third trimester. Stress-dose IV hydrocortisone for labour.

Hypothyroidism: Levothyroxine requirements increase by 25–50% in pregnancy. Monitor free T4 every 4–6 weeks; TSH is unreliable in central hypothyroidism.

Sheehan syndrome (postpartum pituitary necrosis) — consider in any woman with failure to lactate, amenorrhoea and fatigue following obstetric haemorrhage.

👶 Paediatrics

GH deficiency: Paediatric GHD requires stimulation testing (glucagon or arginine preferred over ITT). Recombinant GH (somatropin) 0.025–0.05 mg/kg/day SC. PBS Authority Required for paediatric GHD.

Craniopharyngioma: Most common pituitary-region tumour in children. Hypopituitarism and hypothalamic obesity are major long-term complications requiring multidisciplinary follow-up.

Puberty: GnRH stimulation test essential for differentiating constitutional delay from hypogonadotropic hypogonadism. Retesting after age 18 may be needed.

All paediatric dynamic endocrine testing should be performed at a tertiary paediatric endocrine centre (e.g., Sydney Children's Hospital, RCH Melbourne, QCH Brisbane).

👴 Elderly

ITT contraindicated: Insulin tolerance test is contraindicated in patients >65 years. Use glucagon stimulation test or SST as alternatives.

Testosterone: Age-related testosterone decline (andropause) does not routinely require replacement. Testosterone therapy in elderly men requires careful risk–benefit assessment, including cardiovascular and prostate risk.

Pituitary adenomas: Non-functioning incidentalomas are very common in the elderly. Observation may be appropriate for asymptomatic microadenomas.

🫘 Renal Impairment

Cortisol: Chronic kidney disease may impair cortisol metabolism, leading to altered cortisol levels. Interpret dynamic tests with caution.

SIADH vs CKD: Hyponatraemia in CKD can mimic SIADH; fluid restriction may be poorly tolerated in advanced CKD.

Desmopressin: No significant renal dose adjustment required. Used therapeutically in CKD for uraemic bleeding (high-dose IV).

🫁 Hepatic Impairment

Cortisol binding globulin (CBG): Liver disease reduces CBG, lowering total cortisol but free cortisol may be normal. Free cortisol or salivary cortisol preferred for assessment.

Oestrogen: Oral oestrogens increase CBG; combined oral contraceptive can falsely elevate total cortisol. Use non-oral oestrogen or stop OCP 6 weeks before testing.

🛡️ Immunocompromised

Lymphocytic hypophysitis: Associated with immune checkpoint inhibitor (ICI) therapy (e.g., nivolumab, pembrolizumab). Hypophysitis occurs in 5–10% of patients on anti-CTLA-4 agents. Monitor pituitary function before and during ICI therapy.

HIV: Opportunistic infections (CMV, toxoplasma) can involve the hypothalamus/pituitary. Endocrine screening should be considered in HIV patients with new-onset endocrine symptoms.

ATSI Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of endocrine and metabolic disease that directly and indirectly impacts HPA function and the interpretation of endocrine tests. The following considerations are important in clinical practice:

Diabetes & metabolic syndrome

ATSI peoples have 3–4 times the prevalence of type 2 diabetes compared with non-Indigenous Australians. Insulin resistance affects SHBG levels and alters the interpretation of total testosterone and oestradiol measurements. Obesity-driven pseudo-Cushing syndrome (mild hypercortisolism with obesity) must be distinguished from true Cushing disease.

Rheumatic heart disease

Endocarditis prophylaxis and valvular heart disease may preclude ITT (cardiac contraindication). Use SST or GST as alternatives for adrenal reserve testing.

Remote & rural access

Specialist endocrine services and dynamic testing facilities are concentrated in metropolitan and major regional centres. Telehealth endocrinology consultations are rebatable under Medicare. Use SST (widely available) as the first-line adrenal screening test in remote settings, with ITT/GST referral when available.

Pituitary imaging access

MRI access is limited in many remote communities. CT pituitary (with contrast) is an acceptable initial alternative for macroadenoma assessment, though MRI is preferred for microadenoma and pre-surgical planning. Patient-assisted travel schemes (PATS) in each state/territory can support transfer for MRI.

Traumatic brain injury

ATSI peoples experience higher rates of TBI, particularly in remote communities. Post-TBI hypopituitarism screening should be incorporated into TBI follow-up pathways in ATSI health services.

Culturally safe care

Use Aboriginal and Torres Strait Islander health workers and liaison officers during endocrine consultations. Provide information in plain language and culturally appropriate formats. Respect gender-sensitive examination preferences. Engage with local Aboriginal Community Controlled Health Organisations (ACCHOs) for integrated care.

📚 References

1. Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ. Williams Textbook of Endocrinology. 14th ed. Philadelphia: Elsevier; 2020.
2. Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847–875.
3. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951.
4. Fleseriu M, Hashim IA, Engel T, et al. Hypothalamic–pituitary–adrenal axis dysfunction in adults: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2024;109(1):e1–e16.
5. Higham CE, Johannsson G, Shalet SM. Hypopituitarism. Lancet. 2016;388(10058):2403–2415.
6. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288.
7. Australian Institute of Health and Welfare (AIHW). Diabetes: Australian Facts. Canberra: AIHW; 2023.
8. Royal Australasian College of Physicians (RACP). Position Statement: Aboriginal and Torres Strait Islander Health. Sydney: RACP; 2021.
9. Agha A, Rogers B, Sherlock M, et al. Anterior pituitary dysfunction in traumatic brain injury. Clin Endocrinol. 2004;61(5):581–588.
10. Grossman AB. Clinical review: The diagnosis and management of central hypothyroidism. J Clin Endocrinol Metab. 2024;109(2):e458–e469.
11. Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516–524.
12. Pharmaceuticals Benefits Scheme (PBS). PBS Online. Australian Government Department of Health. Available at: https://www.pbs.gov.au. Accessed 2024.